Published in Breast Cancer Res on August 23, 2010
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell (2012) 1.44
cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res (2012) 1.28
Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res (2012) 1.15
Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control (2013) 1.13
Endothelial induced EMT in breast epithelial cells with stem cell properties. PLoS One (2011) 1.06
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med (2013) 1.01
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med (2013) 0.88
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer (2014) 0.84
Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice. PLoS One (2014) 0.78
LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells. Oncogene (2015) 0.78
Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival. PLoS One (2012) 0.78
Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. PLoS One (2015) 0.77
Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech (2016) 0.77
Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer. Clin Transl Med (2014) 0.76
Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. EBioMedicine (2016) 0.76
Paracrine Met signaling triggers epithelial-mesenchymal transition in mammary luminal progenitors, affecting their fate. Elife (2015) 0.76
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. BMC Cancer (2015) 0.76
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene (2015) 0.75
cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer. Springerplus (2016) 0.75
MET deregulation in breast cancer. Ann Transl Med (2015) 0.75
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med (2017) 0.75
Clinicopathological and prognostic significance of c-Met overexpression in breast cancer. Oncotarget (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Genome maintenance mechanisms for preventing cancer. Nature (2001) 16.17
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol (2006) 7.11
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 6.13
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell (2006) 4.98
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
An entire functional mammary gland may comprise the progeny from a single cell. Development (1998) 4.77
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J (1991) 3.20
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol (1998) 3.05
Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res Treat (1996) 3.00
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res (1995) 2.84
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene (2001) 2.33
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Roles of BRCA1 and its interacting proteins. Bioessays (2000) 2.23
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene (1988) 2.20
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol (2007) 2.20
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98
Detection and analysis of mammary gland stem cells. J Pathol (2009) 1.96
Trastuzumab: triumphs and tribulations. Oncogene (2007) 1.94
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol (1995) 1.94
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer (1999) 1.89
Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med (2006) 1.88
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res (2008) 1.82
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A (2005) 1.70
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol (1996) 1.58
Evolving treatment of advanced colon cancer. Annu Rev Med (2009) 1.56
Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol (1998) 1.56
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev (2008) 1.41
Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene (2003) 1.41
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res (2010) 1.38
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int (2001) 1.20
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res (2006) 1.19
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene (2009) 1.16
c-Met expression in gastric cancer with liver metastasis. Oncology (2002) 1.16
Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev Genet (1996) 1.07
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology (2007) 1.05
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics (2008) 1.04
Endocrine therapy for breast cancer: an overview. Breast (2007) 0.97
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist (2003) 0.95
Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest (1995) 0.93
FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res (2009) 0.92
The Met receptor tyrosine kinase and basal breast cancer. Cell Cycle (2010) 0.90
Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol (1996) 0.86
Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol (2006) 0.78
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol (2002) 2.74
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev (2008) 2.41
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol (2003) 1.79
The Met pathway: master switch and drug target in cancer progression. FASEB J (2006) 1.74
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res (2011) 1.52
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
To move or not to move? Semaphorin signalling in cell migration. EMBO Rep (2004) 1.42
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep (2004) 1.39
The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37
Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med (2003) 1.37
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol (2006) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res (2003) 1.34
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res (2011) 1.32
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. J Cell Sci (2005) 1.31
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res (2004) 1.26
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res (2005) 1.20
Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem (2004) 1.16
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol (2005) 1.10
Functional regulation of semaphorin receptors by proprotein convertases. J Biol Chem (2003) 1.10
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09
Cancer: the matrix is now in control. Nat Med (2005) 1.09
Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs (2010) 1.09
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res (2011) 1.07
Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res (2011) 1.06
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem (2010) 1.06
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06
Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal (2009) 1.02
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res (2014) 1.02
The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem (2010) 1.01
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J Clin Invest (2009) 1.00
The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med (2008) 0.99
Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res (2004) 0.98
Invasive growth: a genetic program. Int J Dev Biol (2004) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Mol Biol Cell (2008) 0.97
"Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res (2008) 0.97
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem (2010) 0.95
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer (2011) 0.93
Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res (2010) 0.93
Genetic link between cancer and thrombosis. J Clin Oncol (2009) 0.93
Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J (2003) 0.92
Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal (2009) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res (2013) 0.90
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. PLoS One (2008) 0.90
NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells. Cancer Res (2014) 0.89
p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer (2006) 0.89
An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol (2002) 0.88
Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci (2003) 0.87
Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J Biol Chem (2003) 0.86
A functional role for hemostasis in early cancer development. Cancer Res (2005) 0.85
The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer (2014) 0.84
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther (2013) 0.84
Invasive growth: a two-way street for semaphorin signalling. Nat Cell Biol (2004) 0.80
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. Hepatology (2008) 0.80
From bench to bedside: does preclinical practice in translational oncology need some rebuilding? J Natl Cancer Inst (2013) 0.79
Feline STK gene expression in mammary carcinomas. Oncogene (2002) 0.79
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer (2014) 0.79